These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20715870)

  • 1. Toward development of targeted nonsteroidal antiandrogen-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-gadolinium complex for prostate cancer diagnostics.
    Marom H; Miller K; Bechor-Bar Y; Tsarfaty G; Satchi-Fainaro R; Gozin M
    J Med Chem; 2010 Sep; 53(17):6316-25. PubMed ID: 20715870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide.
    Payen O; Top S; Vessières A; Brulé E; Plamont MA; McGlinchey MJ; Müller-Bunz H; Jaouen G
    J Med Chem; 2008 Mar; 51(6):1791-9. PubMed ID: 18303829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
    Parent EE; Dence CS; Jenks C; Sharp TL; Welch MJ; Katzenellenbogen JA
    J Med Chem; 2007 Mar; 50(5):1028-40. PubMed ID: 17328524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
    Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
    Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring.
    Kirkovsky L; Mukherjee A; Yin D; Dalton JT; Miller DD
    J Med Chem; 2000 Feb; 43(4):581-90. PubMed ID: 10691684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a benzopyran-containing androgen receptor antagonist to treat antiandrogen-resistant prostate cancer.
    Oh S; Nam HJ; Park J; Beak SH; Park SB
    ChemMedChem; 2010 Apr; 5(4):529-33. PubMed ID: 20135667
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells.
    Saha P; Hödl C; Strauss WS; Steiner R; Goessler W; Kunert O; Leitner A; Haslinger E; Schramm HW
    Bioorg Med Chem; 2010 Mar; 18(5):1891-8. PubMed ID: 20149664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intracellular and nuclear-targeted delivery of an antiandrogen drug by carrier peptides.
    Hodoniczky J; Sims CG; Best WM; Bentel JM; Wilce JA
    Biopolymers; 2008; 90(5):595-603. PubMed ID: 18351583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
    Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR; Lee E; Thompson TA; Basu HS; Ripple MO; Ariazi EA; Wilding G
    Prostate; 2005 May; 63(2):155-68. PubMed ID: 15486991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
    Ellwood-Yen K; Wongvipat J; Sawyers C
    Cancer Res; 2006 Nov; 66(21):10513-6. PubMed ID: 17079473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
    Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
    Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.